Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00126893 · ClinicalTrials.gov registry record · Phase 1
Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia
A Phase 1 study, sponsored by Celgene Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00126893 is a Phase 1 study that was terminated before completion, run by Celgene Corporation. The registered enrollment target is 36 participants.
The verdict
NCT00126893, a Phase 1 study, was terminated before completion, sponsored by Celgene Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a single center Phase 1 study to evaluate the safety, pharmacokinetics and pharmacodynamics of CC-401 in subjects with refractory acute myelogenous leukemia.
Interventions
- DRUG CC-401
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00126893
The ClinicalTrials.gov registry entry for NCT00126893 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CC-401 is the first listed.
NCT00126893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00126893 about?
NCT00126893 is a clinical study titled "Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia". This is a single center Phase 1 study to evaluate the safety, pharmacokinetics and pharmacodynamics of CC-401 in subjects with refractory acute myelogenous leukemia.
What is the current status of trial NCT00126893?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2005-10. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00126893?
The interventions under investigation include: CC-401 (DRUG).
Who is sponsoring clinical trial NCT00126893?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.